Piper Sandler raised the firm’s price target on Ardelyx (ARDX) to $10 from $9 and keeps a Neutral rating on the shares. Total revenue nicely beat consensus by over $11M, and notably, Ibsrela exceeded company-provided consensus by $7M, which the firm thinks highlights the continued strength of Ardelyx’s sales force and patient access pathways. Overall, Piper looks to more formal evidence of Xphozah’s near- and immediate-term outlook, which would leave the firm more constructive on shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX: